DCTH Stock Performance, Insider Transaction and News

DCTH - Delcath Systems, Inc.

Market Cap	43.19M	P/E	-	EPS this Y	55.40%	Ern Qtrly Grth	-
Income	-47.68M	Forward P/E	-4.12	EPS next Y	84.70%	50D Avg Chg	-33.00%
Sales	2.06M	PEG	-0.27	EPS past 5Y	-	200D Avg Chg	-15.00%
Dividend	N/A	Price/Book	N/A	EPS next 5Y	15.00%	52W High Chg	-50.00%
Recommedations	1.80	Quick Ratio	2.00	Shares Outstanding	25.44M	52W Low Chg	71.00%
Insider Own	2.98%	ROA	-84.51%	Shares Float	22.22M	Beta	0.60
Inst Own	28.29%	ROE	-616.55%	Shares Shorted/Prior	821.16K/898.91K	Price	4.00
Gross Margin	69.25%	Profit Margin	-	Avg. Volume	82,175	Target Price	18.40
Oper. Margin	-2,097.22%	Earnings Date	May 10	Volume	144,930	Change	-4.76%

Healthcare | Medical Devices | United States

About Delcath Systems, Inc.

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.

Delcath Systems, Inc. News

04/04/24	Delcath Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
03/26/24	Delcath Systems Inc (DCTH) Reports Mixed Year-End Financials Amidst Strategic Advancements
03/26/24	Delcath Systems Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update
03/23/24	Insiders of Delcath Systems Getting Good Value On Their US$736.5k Investment
03/20/24	Delcath Systems Closes $7 Million Private Placement
03/19/24	Delcath Systems to Host Fourth Quarter and Full Year 2023 Results and Business Update Call
03/18/24	Delcath Systems Appoints Martha S. Rook as Chief Operating Officer
03/15/24	Delcath Systems Announces $7 Million Private Placement
03/08/24	Delcath Systems Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03/08/24	Delcath Systems to Participate in Upcoming Investor Conferences
02/22/24	Delcath Systems Announces Healthcare Setting Locator for HEPZATO™ KIT (melphalan/Hepatic Delivery System)
02/15/24	Retail investors account for 52% of Delcath Systems, Inc.'s (NASDAQ:DCTH) ownership, while institutions account for 40%
01/31/24	Delcath Systems Receives Permanent J-Code (J9248) for HEPZATO™ (melphalan/Hepatic Delivery System) Effective April 1, 2024
01/23/24	Delcath Systems to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference
01/19/24	Delcath Systems, Inc. (NASDAQ:DCTH): Are Analysts Optimistic?
01/16/24	Delcath Systems Announces U.S. Launch and First Commercial Treatment Utilizing HEPZATO KIT™
12/15/23	Insider Buying: Chief Medical Officer Vojo Vukovic Acquires 40,000 Shares of Delcath Systems ...
12/07/23	Delcath Systems Announces Publication by Independent Investigators of a Retrospective Analysis of Quality of Life in the Journal Melanoma Research
11/15/23	Delcath Systems Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11/13/23	Delcath Systems Reports Third Quarter 2023 Results and Provides Business Update

DCTH Chatroom

RangerYun Posted - 20 hours ago

$DCTH Q1 revenue consensus is $2.5M+ isn't this seem a bit aggressive by analysts for Q1 given Moffitt is the only hospital generating revenue in Q1? just seem high

fredster45 Posted - 20 hours ago

$DCTH 11 hospitals are now accepting patient referrals.

kmx_swing Posted - 20 hours ago

$DCTH 6 months chart...

G101SPM Posted - 1 day ago

$DCTH $5.23 bid. DAC (dollar average cost) (2) $3.79 last $2.85 (12.7.23). EXIT $7.00. UPDATE: Delcath amended license, supply and contract manufacturing agreement with Synerx Pharma and Mylan Teoranta (VTRS): The Amendment (i) extends the term of the Agreement to December 31, 2028; (ii) requires Delcath to place purchase orders for the Product at least 210 days before the delivery date; (iii) modifies the price per vial for the Product; and (iv) provides for certain annual price increases for the Product equivalent to the percent increase of the published producer price index for pharmaceutical preparation and manufacturing measured per calendar year.

brunoq14 Posted - 1 day ago

$DCTH Also found on Schwab, Refinitiv target price 18.40, CFRA upgrade from Strong Sell to Sell. Don't know why CFRA started so negative.

brunoq14 Posted - 1 day ago

$DCTH Schwab gives May 9 as the DCTH earnings date.

HypnoTrader Posted - 2 days ago

$DCTH What did yahoo predict about themselves? Must have been a great investment over the years.

brunoq14 Posted - 2 days ago

$DCTH This is the quarter in which Yahoo Finance Analysis predicts that revenue will double from 2.19M to 4.77M, reaching 25.91M by Q4. finance.yahoo.com/quote/DCTH/analysis

scottwiley Posted - 2 days ago

$DCTH I’m crazy long and it’s nice to see the bounce off the lows and I’m not a chartist even though it I believe took out 200 to still being a downtrend

michaelsott Posted - 2 days ago

$DCTH When do you think this will be bought out?

HypnoTrader Posted - 3 days ago

$DCTH what does this have to do with DCTH?

Myardiny_Toe Posted - 3 days ago

$DCTH................ https://www.forbes.com/sites/jakezamansky/2013/08/08/the-great-vampire-squid-keeps-on-sucking/?sh=47c5415e7df8

gatorfuture Posted - 4 days ago

$DCTH was this stock $700millions a share before?

scottwiley Posted - 4 days ago

$DCTH what a pleasant surprise not to have a end of the day fade. I don’t know if this is short covering or earnings coming up and expecting good news. Maybe the warmest turn will continue upward. Best to all

pufferfishcapital Posted - 4 days ago

$DCTH my update on dcth is accessible on substack under pufferfish capital

brunoq14 Posted - 4 days ago

$DCTH The 52 week high is 7.99.

matthew122 Posted - 4 days ago

$DCTH just the beginning. This is the most derisked stock.

scottwiley Posted - 4 days ago

$DCTH nice to see the relative strength coming back up with decent institutional accumulation. Looks like the short is higher. My bag is considerably lighter. Good luck, All.

TradeWinner Posted - 5 days ago

$DCTH Nice. I like it.

Zzzquil Posted - 1 week ago

$DCTH literally my only green position today lol

LudwigVanBeethoven Posted - 1 week ago

$DCTH the year of Delcath? Man .. this was and still is the biggest patience test I ever tracked :) Almost lost it 4q23 :)

brunoq14 Posted - 1 week ago

$DCTH Q2 should look very good in comparison to Q1, and of course all of the 52 week comparisons will be with under 1M.

brunoq14 Posted - 1 week ago

$DCTH Added at 4.37.

brunoq14 Posted - 1 week ago

$DCTH According to the end of March forecast, we should now have seven active sites.

DaD00d Posted - 1 week ago

$DCTH Looks like there were MANY r/s. Haha

brunoq14 Posted - 1 week ago

$DCTH Any time this approaches $4.50, I'm a buyer. With good execution, we should have a productive H2.

brunoq14 Posted - 1 week ago

$DCTH Yahoo Finance analyst estimates 2024 revenue about $26M, with about $19 in the last two quarters. For 2025, over $70M! What kind of stock price would that get us?

brunoq14 Posted - 1 week ago

$DCTH Any chance of beating the Yahoo Finance estimates for Q1? Earnings (0.47), Revenue 2.19M

scottwiley Posted - 2 weeks ago

$DCTH decent relative strength but..

Zzzquil Posted - 2 weeks ago

$DCTH this thing is a rock amid the recent market wide volatility/blood bath. So far...

Analyst Ratings

HC Wainwright & Co.	Buy	Mar 27, 24
Canaccord Genuity	Buy	Sep 7, 23
Roth MKM	Buy	Aug 16, 23
BTIG	Buy	Aug 16, 23
HC Wainwright & Co.	Buy	Aug 15, 23
Canaccord Genuity	Buy	Aug 15, 23
HC Wainwright & Co.	Buy	May 24, 23
Roth MKM	Buy	Mar 28, 23
HC Wainwright & Co.	Buy	Mar 28, 23

Insider Trades	Relationship	Date	Transactions	Cost($)	#Shares	Value($)	#Share Own	SEC Form 4
MICHEL GERARD J	Chief Executive Offi.. Chief Executive Officer	Dec 08	Buy	2.94	34,000	99,960	262,345	12/11/23
Rosalind Advisors, Inc.	Director Director	Nov 17	Buy	2.4041	100,000	240,410	1,038,828	11/21/23
Pennell Sandra	SVP of Finance, PFO.. SVP of Finance, PFO and PAO	Nov 17	Buy	2.43	30,000	72,900	30,000	11/21/23
Vukovic Vojo	Chief Medical Office.. Chief Medical Officer	Nov 16	Buy	2.48	60,000	148,800	60,000	11/20/23
Purpura John	Chief Operating Offi.. Chief Operating Officer	Oct 13	Buy	3.44	14,505	49,897	41,526	10/17/23
Sylvester John Richard	Director Director	Aug 21	Buy	4.80	10,550	50,640	10,550	08/23/23
MICHEL GERARD J	Chief Executive Offi.. Chief Executive Officer	Mar 29	Buy	4.84	19,646	95,087	197,235	03/30/23
Rosalind Advisors, Inc.	Director Director	Dec 14	Buy	3.6178	15,215	55,045	459,315	12/16/22
SALAMON STEVEN A J	Director Director	Dec 14	Buy	3.6178	15,215	55,045	455,315	12/16/22
MICHEL GERARD J	Chief Executive Offi.. Chief Executive Officer	Dec 13	Buy	2.90	51,725	150,002	177,589	12/14/22
MICHEL GERARD J	Chief Executive Offi.. Chief Executive Officer	Jul 20	Buy	3.98	62,814	250,000	125,864	07/21/22
Purpura John	Chief Operating Offi.. Chief Operating Officer	May 16	Buy	4.61	3,300	15,213	27,021	05/18/22
SALAMON STEVEN A J	Director Director	May 13	Buy	5.027	5,000	25,135	440,100	05/16/22
SALAMON STEVEN A J	Director Director	May 12	Buy	4.904	6,000	29,424	29,424	05/13/22
Rosalind Advisors, Inc.	Director Director	Apr 19	Buy	6.25	1,600	10,000	433,100	04/21/22
SALAMON STEVEN A J	Director Director	Apr 19	Buy	6.25	1,600	10,000	429,100	04/20/22
Rosalind Advisors, Inc.	Director Director	Apr 18	Buy	6.3487	2,000	12,697	431,500	04/19/22
Aharon Gil	Director Director	Apr 18	Buy	6.3487	2,000	12,697	404,000	04/19/22
MICHEL GERARD J	See Remarks See Remarks	Apr 18	Buy	6.36	2,000	12,720	63,050	04/18/22
Rosalind Advisors, Inc.	Director Director	Apr 13	Buy	6.45	1,500	9,675	429,500	04/14/22
SALAMON STEVEN A J	Director Director	Apr 13	Buy	6.45	1,500	9,675	427,500	04/14/22
Rosalind Advisors, Inc.	Director Director	Apr 12	Buy	6.48	2,500	16,200	428,000	04/12/22
SALAMON STEVEN A J	Director Director	Apr 12	Buy	6.48	2,500	16,200	425,000	04/12/22
Rosalind Advisors, Inc.	Director Director	Apr 06	Buy	6.45	2,000	12,900	425,500	04/08/22